Rothschild & Co. Asset Management US Inc. Lowers Position in PRA Health Sciences Inc (NASDAQ:PRAH)

Rothschild & Co. Asset Management US Inc. cut its stake in shares of PRA Health Sciences Inc (NASDAQ:PRAH) by 0.6% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 232,366 shares of the medical research company’s stock after selling 1,378 shares during the period. Rothschild & Co. Asset Management US Inc. owned about 0.35% of PRA Health Sciences worth $23,039,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in PRAH. Motco lifted its position in shares of PRA Health Sciences by 937.0% in the first quarter. Motco now owns 280 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 253 shares in the last quarter. Financial Gravity Wealth Inc. purchased a new position in shares of PRA Health Sciences in the first quarter valued at about $53,000. Manchester Capital Management LLC purchased a new position in shares of PRA Health Sciences in the first quarter valued at about $57,000. CENTRAL TRUST Co lifted its position in shares of PRA Health Sciences by 28.2% in the first quarter. CENTRAL TRUST Co now owns 842 shares of the medical research company’s stock valued at $93,000 after acquiring an additional 185 shares in the last quarter. Finally, Carroll Financial Associates Inc. lifted its position in shares of PRA Health Sciences by 7.6% in the first quarter. Carroll Financial Associates Inc. now owns 1,517 shares of the medical research company’s stock valued at $167,000 after acquiring an additional 107 shares in the last quarter. Institutional investors own 99.84% of the company’s stock.

Shares of NASDAQ:PRAH traded down $0.53 during mid-day trading on Wednesday, reaching $97.37. The stock had a trading volume of 7,234 shares, compared to its average volume of 545,498. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.99 and a current ratio of 0.99. The firm has a market cap of $6.43 billion, a P/E ratio of 24.68, a P/E/G ratio of 1.31 and a beta of 1.12. PRA Health Sciences Inc has a 1 year low of $82.12 and a 1 year high of $121.98. The business has a 50 day moving average of $98.54.

PRA Health Sciences (NASDAQ:PRAH) last posted its earnings results on Wednesday, July 31st. The medical research company reported $1.22 EPS for the quarter, topping analysts’ consensus estimates of $1.11 by $0.11. The company had revenue of $763.31 million for the quarter, compared to the consensus estimate of $764.95 million. PRA Health Sciences had a return on equity of 26.64% and a net margin of 5.39%. The firm’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same period in the previous year, the business earned $1.00 earnings per share. As a group, equities research analysts anticipate that PRA Health Sciences Inc will post 4.61 EPS for the current year.

Several equities analysts have recently commented on the company. BidaskClub upgraded PRA Health Sciences from a “hold” rating to a “buy” rating in a research report on Wednesday, July 24th. Leerink Swann assumed coverage on PRA Health Sciences in a research report on Tuesday, July 2nd. They issued a “market perform” rating and a $105.00 target price on the stock. Mizuho set a $100.00 target price on PRA Health Sciences and gave the stock a “hold” rating in a research report on Friday, May 3rd. Svb Leerink reiterated a “market perform” rating on shares of PRA Health Sciences in a research report on Tuesday, July 2nd. Finally, ValuEngine downgraded PRA Health Sciences from a “buy” rating to a “hold” rating in a research report on Saturday, April 13th. Eight research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. PRA Health Sciences currently has a consensus rating of “Hold” and an average price target of $113.40.

PRA Health Sciences Profile

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Recommended Story: Diversification in Your Portfolio

Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences Inc (NASDAQ:PRAH).

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.